Cargando…
Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection
Better understanding of antibody responses against SARS-CoV-2 after natural infection might provide valuable insights into the future implementation of vaccination policies. Longitudinal analysis of IgG antibody titers was carried out in 32 recovered COVID-19 patients based in the Umbria region of I...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325385/ https://www.ncbi.nlm.nih.gov/pubmed/34343708 http://dx.doi.org/10.1016/j.clim.2021.108814 |
_version_ | 1783731550752342016 |
---|---|
author | Dehgani-Mobaraki, Puya Zaidi, Asiya Kamber Yadav, Nidhi Floridi, Alessandro Floridi, Emanuela |
author_facet | Dehgani-Mobaraki, Puya Zaidi, Asiya Kamber Yadav, Nidhi Floridi, Alessandro Floridi, Emanuela |
author_sort | Dehgani-Mobaraki, Puya |
collection | PubMed |
description | Better understanding of antibody responses against SARS-CoV-2 after natural infection might provide valuable insights into the future implementation of vaccination policies. Longitudinal analysis of IgG antibody titers was carried out in 32 recovered COVID-19 patients based in the Umbria region of Italy for 14 months after Mild and Moderately-Severe infection.Two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein (NCP) and anti-spike-receptor binding domain (S-RBD) were used for sequential serological tests at different time points. The demographics,clinical history and symptom profile associated with the magnitude and longevity of antibody responses were also analyzed. Anti-S-RBD IgG persisted in 96.8% (31 of 32) subjects at 14 months. Patients reporting loss of smell and taste during the clinical course of the disease developed significantly higher antibody titers. Anti-NCP IgG seronegative patients(n=7) at 10 months, tested positive for anti-S-RBD IgG at 12,13 and 14 months emphasizing on a higher false-negative rate for NCP protein-based antibody assays. This study also highlights the importance of adopting specific immunoassays for routine estimation of antibody titers and the decreased rate of re-infections in recovered patients. |
format | Online Article Text |
id | pubmed-8325385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83253852021-08-02 Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection Dehgani-Mobaraki, Puya Zaidi, Asiya Kamber Yadav, Nidhi Floridi, Alessandro Floridi, Emanuela Clin Immunol Full Length Article Better understanding of antibody responses against SARS-CoV-2 after natural infection might provide valuable insights into the future implementation of vaccination policies. Longitudinal analysis of IgG antibody titers was carried out in 32 recovered COVID-19 patients based in the Umbria region of Italy for 14 months after Mild and Moderately-Severe infection.Two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein (NCP) and anti-spike-receptor binding domain (S-RBD) were used for sequential serological tests at different time points. The demographics,clinical history and symptom profile associated with the magnitude and longevity of antibody responses were also analyzed. Anti-S-RBD IgG persisted in 96.8% (31 of 32) subjects at 14 months. Patients reporting loss of smell and taste during the clinical course of the disease developed significantly higher antibody titers. Anti-NCP IgG seronegative patients(n=7) at 10 months, tested positive for anti-S-RBD IgG at 12,13 and 14 months emphasizing on a higher false-negative rate for NCP protein-based antibody assays. This study also highlights the importance of adopting specific immunoassays for routine estimation of antibody titers and the decreased rate of re-infections in recovered patients. Elsevier Inc. 2021-09 2021-07-31 /pmc/articles/PMC8325385/ /pubmed/34343708 http://dx.doi.org/10.1016/j.clim.2021.108814 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Full Length Article Dehgani-Mobaraki, Puya Zaidi, Asiya Kamber Yadav, Nidhi Floridi, Alessandro Floridi, Emanuela Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection |
title | Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection |
title_full | Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection |
title_fullStr | Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection |
title_full_unstemmed | Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection |
title_short | Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection |
title_sort | longitudinal observation of antibody responses for 14 months after sars-cov-2 infection |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325385/ https://www.ncbi.nlm.nih.gov/pubmed/34343708 http://dx.doi.org/10.1016/j.clim.2021.108814 |
work_keys_str_mv | AT dehganimobarakipuya longitudinalobservationofantibodyresponsesfor14monthsaftersarscov2infection AT zaidiasiyakamber longitudinalobservationofantibodyresponsesfor14monthsaftersarscov2infection AT yadavnidhi longitudinalobservationofantibodyresponsesfor14monthsaftersarscov2infection AT floridialessandro longitudinalobservationofantibodyresponsesfor14monthsaftersarscov2infection AT floridiemanuela longitudinalobservationofantibodyresponsesfor14monthsaftersarscov2infection |